JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: CBL0137 (formerly known as Curaxin 137 or CBL-0137) is an inhibitor of the histone chaperone, FACT (facilitates chromatin transcription complex). It also activates p53 and inhibits NF-kB with EC50s of 0.37 uM and 0.47 uM in the cell-based p53 and NF-kB reporter assays, respectively. CBL0137 has entered clinical trials for Glioblastoma and Hematological Malignancies. CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Curaxins modulate several important signaling pathways involved in the pathogenesis of Pancreatic ductal adenocarcinoma (PDA) through inhibition of chromatin remodeling complex FACT. FACT is overexpressed in multiple types of tumor, with one of the highest rate of overexpression in PDA (59%).
References: Oncotarget. 2014 Nov 30; 5(22):11038-53; Sci Transl Med. 2011 Aug 10; 3(95):95ra74.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!